Pharmacokinetic analysis of ductal carcinoma in situ of the breast using dynamic MR mammography
Pharmacokinetic analysis of ductal carcinoma in situ of the breast using dynamic MR mammography
复制标题
DOI：
10.1007/s00330-005-2661-9
复制
发表时间：
2005-07-01
影响因子：
5.9
通讯作者：
Miyazaki, M
中科院分区：
文献类型：
--
作者：
Oshida, K;Nagashima, T;Miyazaki, M
本研究的目的是评估动态磁共振成像的功能参数与乳腺导管原位癌（DCIS）和浸润性灶DCIS的组织学表现之间的关系，并评估这些参数是否可以预测DCIS患者的预后。通过对39例经针活检证实的原发性DCIS患者进行动态MR乳房x线摄影的多室药代动力学分析，确定了振幅A和k（21）两个参数。术后观察肿瘤组织学特征，包括微血管密度（MVD）（抗cd -34）、血管通透性（抗vegf抗原）及组织学分级。组织学显示单纯DCIS 27例，浸润性病灶12例。在单纯DCIS中，MVD与振幅A呈正相关(r=0.56， P
The purpose of this study was to assess the relationship between functional parameters derived from dynamic MR imaging and the histological findings of breast ductal carcinoma in situ (DCIS) and DCIS with invasive foci, and to evaluate whether these parameters might predict DCIS patient outcome. Two parameters, amplitude A and k(21), were determined from multicompartmental pharmacokinetic analyses of dynamic MR mammography in 39 patients with needle biopsy-proven primary DCIS. After surgery, the histological tumor characteristics, including microvessel density (MVD) (anti-CD-34), vascular permeability (anti-VEGF antigen) and histological grade, were evaluated. Histology revealed 27 pure DCIS and 12 DCIS with invasive foci. In pure DCIS, positive correlations between MVD and amplitude A (r=0.56, P